The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

May 07, 2023

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

May 05, 2023

Anne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options

May 03, 2023

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

May 02, 2023

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

May 01, 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

April 27, 2023

Anne M. Noonan, MBBCh, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma.

April 18, 2023

Ann-Kathrin Eisfeld, MD, discusses recent changes to the classification of acute myeloid leukemia, and potential challenges accompanying these new guidelines.

April 14, 2023

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

April 06, 2023

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

April 04, 2023

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

April 04, 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.

March 29, 2023

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

February 22, 2023

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

January 06, 2023

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

January 02, 2023

Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.

January 01, 2023

Incidence of surgery refusal has increased by nearly 50% among Black and Hispanic women with potentially curable, nonmetastatic breast cancer over the past decade, according to findings from an analysis of Surveillance, Epidemiology, and End Results Program data.

December 29, 2022

Claire F. Verschraegen, MD, discusses how nivolumab and ipilimumab fit into the treatment paradigm, poses examples of when treatment-related adverse effects might influence which agents to use, and emphasizes the importance of considering the benefits of immunotherapy.

December 19, 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

December 09, 2022

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

December 07, 2022

Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.